Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert D Knight

Showing results (41-50 of 42) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 42 results.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Pageof 5

Showing results (41-50 of 42) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 42 results.
Blood|September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza, James A Reeves, Eric J Feldman, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Pageof 5